GlassScriptPhysician profile
April D Ebersole
NPI 1447245956
$1,886.75
in general payments reported to CMS, 2019-2025
18 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80.32 · 2022: $27.96 · 2023: $42.39 · 2024: $280 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,778.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,778.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $447.63 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $264.36 | 2024-2025 | Rexulti |
| Lundbeck LLC | $241.43 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $231.26 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $134.71 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.79 | 2025 | Caplyta |
| Neurocrine Biosciences, INC. | $108.82 | 2025 | |
| Alkermes, INC. | $49.60 | 2025 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $47.29 | 2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $46.78 | 2025 | Trintellix |
| Tris Pharma INC | $38.14 | 2025 | Dyanavel Xr |
| Sun Pharmaceutical Industries INC. | $27.42 | 2021 | |
| Avanir Pharmaceuticals, INC. | $26.23 | 2021 | |
| Supernus Pharmaceuticals, INC. | $24.98 | 2025 | Qelbree |
| Braeburn INC. | $24.87 | 2024 | Brixadi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.40 | 2023 | Wegovy |
| Acadia Pharmaceuticals INC | $14.19 | 2021 | |
| Lilly USA, LLC | $13.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Ebersole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.